Page 98 - 2019_03-Haematologica-web

S. Park et al.
One. 2011;6(8):e23109.
26. Kautz L, Jung G, Du X, et al. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of beta- thalassemia. Blood. 2015;126(17):2031- 2037.
27. Ramirez JM, Schaad O, Durual S, et al. Growth differentiation factor 15 produc- tion is necessary for normal erythroid dif- ferentiation and is increased in refractory anaemia with ring-sideroblasts. Br J Haematol. 2009;144(2):251-262.
28. Lefebvre T, Lasocki S, Feneant-Thibault M, et al. Added value of hepcidin quantifica- tion for the diagnosis and follow-up of ane- mia-related diseases. Ann Biol Clin (Paris). 2017;75(1):9-18.
29. van der Vorm LN, Hendriks JC, Laarakkers CM, et al. Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material. Clin Chem. 2016;62(7):993-1001.
30. Meunier M, Ancelet S, Lefebvre C, et al. Reactive oxygen species levels control NF- kappaB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget. 2017;8(62):105510-105524.
31. Westers TM, Alhan C, Chamuleau ME, et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood. 2010;115(9):1779-1784.
32. Alhan C, Westers TM, Cremers EM, et al. High flow cytometric scores identify adverse prognostic subgroups within the revised International Prognostic Scoring System for myelodysplastic syndromes. Br J Haematol. 2014;167(1):100-109.
33. Alhan C, Westers TM, van der Helm LH, et al. Absence of aberrant myeloid progenitors by flow cytometry is associated with favor- able response to azacitidine in higher risk myelodysplastic syndromes. Cytometry B Clin Cytom. 2014;86(3):207-215.
34. Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017;8(43):73483-73500.
504
haematologica | 2019; 104(3)